Market Place
Sourcing Support
GT Biopharma Reports Third Quarter 2024 Financial Results
14 Nov 2024 //
GLOBENEWSWIRE
GT Biopharma To Participate In ROTH Healthcare Conference
26 Sep 2024 //
GLOBENEWSWIRE
GT Biopharma to Host Virtual Event on NK Cell Engager Oct 10
24 Sep 2024 //
GLOBENEWSWIRE
GT Biopharma Reports Q2 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
GT Announces FDA Clearance of Investigational IND Application for GTB-3650
27 Jun 2024 //
GLOBENEWSWIRE
GT Biopharma Announces $3.2M Registered Direct Offering
21 May 2024 //
GLOBENEWSWIRE
GT Biopharma Reports Q1 2024 Financial Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
26 Mar 2024 //
GLOBENEWSWIRE
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
01 Feb 2024 //
GLOBENEWSWIRE
GT Biopharma Stockholders Vote FOR All Proposed Items at Special Meeting
06 Dec 2023 //
GLOBENEWSWIRE
GT Bio Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
04 Dec 2023 //
GLOBENEWSWIRE
GT Biopharma Presented Positive Preclinical Data for GTB-5550
06 Nov 2023 //
GLOBENEWSWIRE
GT Biopharma Reports Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
GT Biopharma Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
GT Biopharma to Participate in H.C. Wainwright Immune Cell Engager Conference
03 Aug 2023 //
GLOBENEWSWIRE
GT Biopharma Reports 1Q 2023 FYR Results and Provides Corporate Update
15 May 2023 //
GLOBENEWSWIRE
GT Biopharma Names Charles J. Casamento to the Board of Directors
04 May 2023 //
GLOBENEWSWIRE
GT Biopharma Reports 4Q and Reports 2022 FYR and Provides Corporate Update
30 Mar 2023 //
GLOBENEWSWIRE
GT Biopharma to Participate in Wainwright Cell Therapy Virtual Conference
24 Feb 2023 //
GLOBENEWSWIRE
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
02 Feb 2023 //
GLOBENEWSWIRE
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering
30 Dec 2022 //
GLOBENEWSWIRE
GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
14 Dec 2022 //
GLOBENEWSWIRE
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting
12 Dec 2022 //
GLOBENEWSWIRE
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach
03 Nov 2022 //
GLOBENEWSWIRE
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results
31 Oct 2022 //
GLOBENEWSWIRE
GT Biopharma Announces Two Poster Presentations at the (SITC) 37th Meeting
06 Oct 2022 //
GLOBENEWSWIRE
GT Biopharma Announces Adjournment of Special Shareholders Meeting
04 Oct 2022 //
GLOBENEWSWIRE
GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022
12 Sep 2022 //
GLOBENEWSWIRE
GT Biopharma to Participate in the H.C. Wainwright 24th Annual GHC in September
08 Sep 2022 //
GLOBENEWSWIRE
Cytovance Signs Service Agreement with GT Biopharma
02 Sep 2022 //
CONTRACTPHARMA
Cytovance Signs Service Agreement with GT Biopharma
02 Sep 2022 //
CONTRACT PHARMA
GT Biopharma Affirms Manufacturing Timeline For Lead Asset GTB-3650
30 Aug 2022 //
GLOBENEWSWIRE
GT Biopharma Reports Second Quarter Fiscal 2022 FY Results & Business Update
11 Aug 2022 //
GLOBENEWSWIRE
GT Biopharma Presents PC Data on Second-Gen CD19 Targeting TriKE
10 Jun 2022 //
GLOBENEWSWIRE
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
GT Biopharma to Participate at H.C. Wainwright Hybrid Conference
12 May 2022 //
GLOBENEWSWIRE
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+GTB-5550 at AACR
11 Apr 2022 //
GLOBENEWSWIRE
GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results
28 Mar 2022 //
PRNEWSWIRE
GT Biopharma Presents GTB-5550 Preclinical MM Proof-of-Concept Data
21 Mar 2022 //
PRNEWSWIRE
GT Bio Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE
09 Mar 2022 //
PRNEWSWIRE
GT Biopharma Appoints Manu Ohri as Chief Financial Officer
18 Feb 2022 //
PRNEWSWIRE
GT BioPharma Reports Q3 2021 Financial Results and Provides Corporate Update
10 Nov 2021 //
PRNEWSWIRE
GT Biopharma Advances GTB-3650 Into IND-Enabling Studies
13 Sep 2021 //
BIOSPACE
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform
09 Sep 2021 //
BIOSPACE
GT Biopharma to Present at Upcoming September Investor Conferences
08 Sep 2021 //
PRNEWSWIRE
GT Biopharma Announces the Promotion of Dr. Gregory Berk
23 Aug 2021 //
PRNEWSWIRE
GT Biopharma Provides Second Quarter 2021 Business Update
13 Aug 2021 //
PR NEWSWIRE
GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results
06 Aug 2021 //
PRNEWSWIRE
Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial
21 Jun 2021 //
PRNEWSWIRE
GT Biopharma to Present at Raymond James Human Health Innovation Conference
16 Jun 2021 //
PRNEWSWIRE
GT Biopharma Announces Update On The Commencement Of GTB-3550 Ph2 Trial
12 May 2021 //
PRNEWSWIRE
GT Biopharma Announces Update On The Commencement Of The GTB-3550
11 May 2021 //
PRNEWSWIRE
GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell
13 Apr 2021 //
PRNESWIRE
GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell
13 Apr 2021 //
PRNESWIRE
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™
08 Apr 2021 //
PRNEWSWIRE
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550
08 Apr 2021 //
PRNEWSWIRE
NK Disruptor GT Biopharma Advances Cancer Serial Killer TriKEs
29 Mar 2021 //
FIERCEBIOTECH
GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results
17 Mar 2021 //
PRNEWSWIRE
GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results
17 Mar 2021 //
PRNEWSWIRE
GT Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site
04 Mar 2021 //
PRNEWSWIRE
